The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

INTRODUCTION: To save costs to the healthcare system, forced non-medical switch (NMS) policies that cut drug coverage for originator biologics and fund only less expensive biosimilars are being implemented. However, costs related to the impact of NMS on healthcare resource utilization (HCRU) must al...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillhouse, Erin, Mathurin, Karine, Bibeau, Joëlle, Parison, Diana, Rahal, Yasmine, Lachaine, Jean, Beauchemin, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799532/
https://www.ncbi.nlm.nih.gov/pubmed/34780028
http://dx.doi.org/10.1007/s12325-021-01951-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799532/
https://www.ncbi.nlm.nih.gov/pubmed/34780028
http://dx.doi.org/10.1007/s12325-021-01951-z

Ejemplares similares